Dissemination (Meeting Coverage)

Results from the phase 2 clinical trial DESTINY-Breast01 showed that the investigational human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate [Fam-] trastuzumab deruxtecan (T-DXd) has just as durable...

Updated findings of the PACIFIC trial showed an overall survival (OS) rate of 43% after 5 years of treatment with durvalumab, which has . Physician’s Weekly spoke with Dr. Camille Hertzka, vice president and head of Oncology, US...

For a presentation at ASCO 2021, John Seymour, PhD, Professor at the Peter MacCallum Cancer Centre of the Royal Melbourne Hospital and University of Melbourne in Australia, discussed six FDA-approved agents or drug...

For a review presented at ASCO 2021, Sonali M. Smith, MD, FASCO, Elwood V. Jensen Professor in Medicine and Chief of the Section of Hematology/Oncology at the University of Chicago, discussed the findings of two studies focused...

TG-1701 (TG Therapeutics) is an investigational, once-daily, selective, convalent, oral Bruton tyrosine kinase inhibitor. Prior research has shown that inhibition of Bruton tyrosine kinase is superior to standard...

Genetic testing for BRCA1/2 mutations is recommended for all women with ovarian cancer, given the important implications for treatment and prognosis, according to the Caitlin E. Taylor, MD, lead author of a paper presented at...

It has long been identified that Black women with ovarian cancer have worse overall survival when compared to White women, explains Deanna L Huffman, DO, Department of Internal Medicine, Allegheny Health Network, in Pittsburgh....

Effective patient-clinician communication (PCC) is central to the delivery of high-quality care, according to the National Cancer Institute (NCI), and it becomes even more crucial in the cancer setting where patients deal with...

A better understanding of the burden of treatment side effects in patients with gynecological malignancies could help guide symptom interventions and oncologic therapy decision-making, according to Ashley D. Hickman, MD, the...

Adavosertib with or without olaparib shows efficacy in women with PARP inhibitor-resistant ovarian cancer (Abstract #5505) Clinical trial results from the randomized, non-comparative Phase II EFFORT study showed that...

Median overall survival doubled for veterans with stage 3 non-small cell lung cancer who received chemoradiotherapy plus durvalumab, as compared to those receiving chemoradiotherapy alone, according to a new study presented at...

Since the 1950s, when the movement disorder tardive dyskinesia (TD) was first described, several drugs have been studied for potential effectiveness or used off-label for the treatment of TD, but none provided clear evidence of...

Final results from the head-to-head ELEVATE-RR Phase III trial of acalabrutinib demonstrated non-inferior progression-free survival (PFS) and statistically significantly fewer events of atrial fibrillation versus ibrutinib in...

The phase III PAOLA-1/ENGOT-ov25 trial evaluated the addition of maintenance olaparib to bevacizumab in women with advanced ovarian cancer who were in response after first-line platinum-based CTx with bevacizumab. In the Phase...

Clinical trial results from the randomized, non-comparative Phase II EFFORT study showed that adavosertib, a Wee1 inhibitor, was effective in patients with PARP inhibitor-resistant ovarian cancer when given alone and in...

TG-1701 (TG Therapeutics) is an investigational, once-daily, selective, convalent, oral Bruton tyrosine kinase inhibitor. Prior research has shown that inhibition of Bruton tyrosine kinase is superior to standard...